Clinical Letter

Clinical effects of omega-3 fatty acids on acne vulgaris

DOI: 10.1111/ddg.14779

Dear Editors,

There is growing evidence highlighting the impact of nutrition on the severity of acne [1, 2]. Dietary interventions for acne patients, in addition to pharmacotherapy are therefore being investigated. Yet, data on the impact of Omega-3 fatty acids (ω -3 FA), which may contribute to alleviate the clinical severity through reduced sebum production and keratinization of the pilosebaceous unit, is scarce [3, 4] (Figure 1 a, b).

A systematic review screening Cochrane, Embase and PubMed for "acne" and "omega-3-fatty acids" was conducted to assess all prospective, interventional clinical trials with oral supplementation of ω -3 FA evaluating the effects on acne based on clinical scores (Figure 2). Three trials were included in the present review (Table 1).

Rubin et al. conducted a study with five patients in 2008 [5]. After an eight-week supplementation of *eicosapentae-noic acid* (EPA), combined with micronutrients and a green tea antioxidant, a decrease in the lesion count from 62.8 to 40.4 was seen in 4/5 patients. Hereby, a reduction of inflammatory lesions was observed from 20.8 to 6.8. Furthermore, a mean improvement in patients' self-evaluated mental status by 24 % according to a standardized questionnaire was seen.

This pilot study may serve as a motivation to pursue future investigations; however, no clinical recommendations can be drawn from the presented cases. Results were not significant, possibly due to the extremely small patient collective. Notably, since patients took a combination of supplements, the described clinical improvement could not be attributed to ω -3 FA alone. Future trials should therefore include a larger patient cohort and focus on isolated supplementation.

In 2012, Khayef et al. investigated the effects of *doco-sahexaenoic acid* (DHA) and *docosapentaenoic acid* (DPA) in 13 males [6]. In addition to the lesion count, the authors investigated patients' skin redness and assessed a three-day food diary. No significant differences were found when comparing baseline lesion count to 12-week post-intervention. However, scores of 8/13 individuals improved, with 7/8 entering the study with moderate to severe appearances. In 4/13 patients, acne's grade worsened, with 3/4 patients presenting with mild acne at baseline. These findings raise the question whether patients with a more severe degree of acne might

have lower blood levels of ω -3 FA compared to milder cases and might therefore profit more from an oral supplementation.

Check for updates

Limitations of this study are the small patient cohort without a control group and exclusion of female patients. Unfortunately, it could not be determined which acne treatment was allowed during the trial. It might only be speculated that "no intense treatment" might have excluded isotretinoin treatment. Future investigations should clearly state exclusion and inclusion criteria and prescription therapy should not be allowed to reduce bias.

Jung et al. conducted a randomized, double-blinded, controlled trial in 2014, with a male dominated study cohort of 46 patients [7]. The collective was divided into two treatment groups (ω -3 FA or ω -6 FA), and one control group. Apart from the lesion count, daily food reports, the extent of facial inflammation and patients' self-evaluated acne severity were assessed. Additionally, 2-mm punch biopsies were taken from inflammatory facial lesions.

Both treatment groups showed significant improvements compared to the control, but no significant differences were found between them. Patients' mean lesion counts and subjective ratings decreased. Immunohistology staining intensities diminished in both treatment groups, whereas no significant change was observed in the control group.

Out of the three reviewed trials, Jung et al. conducted the highest-quality study. Immunohistochemical analyses impressively demonstrated reduced inflammatory markers, bearing in mind that the location of a punch biopsy was examiner dependent. Interestingly, ω -3 and ω -6 FA both led to a clinical improvement, with no significant difference between the two groups. This finding contradicts preliminary data arguing that ω -6 FA foster inflammation. However, levels of FA as well as their bioavailability differ greatly between individuals, which might be a reason for the contradictory results [8]. Blood levels should therefore be regularly checked in future studies to establish baseline values, ensure sufficient availability and potentially even allow for adjustment of dosage throughout the study [9].

Despite the physiological anti-inflammatory mechanisms of ω -3 FA, the investigated trials showed inconclusive results possibly due to great limitations. Outlined conclusions should be implemented in future trials to elaborate whether ω -3 FA are effective in reducing acne severity.

Acknowledgment

Open access funding enabled and organized by Projekt DEAL.

Conflict of interest None.






Figure 1 (a) Hyperglycemic foods and dairy products, especially whey protein, stimulate the synthesis of Insulin-like growth factor (IFG)-1, one of the central nutritive acne-inducers. IGF-1 activates the mammalian target of rapamycin complex 1 (mTORC1), which in turn triggers the transcription of Sterol response element-binding protein (SREBP)-1. SREBP-1 stimulates sebum production, hyperkeratinization of follicles and pro-inflammatory mediators. ω -3 FA inhibit IGF-1 and decrease inflammation by stimulating the production of PGE, PGE₃ and LTB₅. ω -6 FA are thought to foster inflammatory processes, e. g. via PGE₂ or LTB₄. *In vitro* and preliminary *in vivo* data show beneficials effects of probiotics on acne, including inhibitory mechanisms of C. acnes proliferation and reduced levels of IGF-1.

(b) Polyunsaturated fatty acids (PUFAs) including ω -3 FA with the first double bound in the third position of the carbon-carbon fatty acid chain and ω -6 FA with the first double bound in the sixth position. Sources of ω -3 FA (e. g., alpha-linoleic acid [ALA], eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA]) are nuts, seeds (chia-, hemp-, linseeds) and algae (through algae intake also salmon, herring, sardines, seafood). ω -6 FA (e. g., arachidonic acid [AA], gamma-linoleic acid [GLA]) are found in sunflower oil and corn oil.





A٦ ٤-۵، fo noitsulsv∃ اوvel؟	°z	° Z	°Z
Control group?	None	None	Yes, but no pla- cebo
SnoitezimobneA	°Z	° Z	Kes
Secondary study endpoints	Mental health status via Arizona Integrative Outco- mes Scale (AIOS)	Skin redness (L*a*b*color sys- tem; Commission Internationale de L'Eclairage)	Effect of dietary Jung /r et al. Zord Croup :: Drupple 1000 mg 100 means 18-33 No prescrit Lesion Severity grading Yes, versity No supplemen- tation with supplemen- tation with trion Supple- frict EPA (fish oil) 10000 mg weeks (week 36 males 18-33 No prescrit Lesion Severity grading Yes, but no No supplemen- tation with orega-s fat- trion EPA (fish oil) 10000 mg weeks (week 36 males 18-33 No prescrit but no supplemen- tation with orega-s fat- trion Eroup z: S, 10) Group z: No other mation based pla- graphs (cunfife pla- graphs (cunfife y acid and gamma-lino- gamma-lino- gamma-lino- bene ando- set out Association n = 15 No other ments affer assis- graphs (cunfife pla- graphs (cunfife pla- graphs (cunfife y acid and gamma-lino- gamma-lino- bene blind, No supple- graphs n = 15 No previ- graphs (cunfife pla- graphs (cunfife pla- graphs (cunfife x a rando- bene blind, No syste- ments No syste- graning intensity
Primary study endpoint	Lesion count	Lesion count	count
Conditions during intervention	No prescri- bed acne treatments No other supple- ments or lifestyle changes	No "inten- se" acne treatment No additi- o nal intake of ω -3 FA- rich foods	No prescri- bed acne treatment No other supple- ments No previ- ous syste- mic acne treatment
Age range (years)	18– 23	18-40	18-33
Number (n) and gender of patients	n = 5 3 males 2 females	n = 13 13 males	n = 45 36 males 9 females <i>Group 1:</i> n = 15 <i>Group 2:</i> n = 15 n = 15
Study Visits	n = 2 (week o, 8)	n = 3 (week 0, 6, 12)	n = 10 (week 0, 2, 5, 10)
Time period of intervention	8 weeks	12 weeks	w eeks
əpszod ylisd	250 mg 50 mg 51 ng 50 ng 50 ng	930 mg 720 mg 174 mg	1000 mg 1000 mg 400 mg
nipiro bns ztnəməlqqu2	EPA (sardines, anchovies) Epigallocate- chin gallate (EGCC, green tea extract) Zinc gluconate Selenium Chromium	EPA (fish oil) DHA (fish oil) DPA (fish oil)	<i>Group 1:</i> EPA (fish oil) DHA (fish oil) <i>Group 2:</i> GLA (borage oil) <i>Group 3:</i> No supple- mentation
Rotnoviation for the second	Oral Supple- menta- tion	Oral Supple- menta- tion	Oral Supple- tion
Year of publication	2008	2012	2014
sıodtuA	Rubin MG, K Kim and A Logan	Khayef G et al.	Jung JY et al.
əltiT	Acne vulga- ris, mental health and omega-3 fatty acids: a report of cases.	Effects of fish oil supplemen- tation on in- flammatory acne.	Effect of dietary supplemen- tation with omega-3 fat- ty acid and gamma-lino- lenic acid on acne vulga- ris: a rando- mized, dou- ble-blind, trial

Anne Guertler¹, Katharina Neu¹, Tobias Fiedler¹, Anne-Charlotte Kuna¹, Till Kämmerer¹, Diana Lill¹, Lars E. French^{1,2}, Markus Reinholz¹

 (1) Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
(2) Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, FL, USA

Correspondence to

Dr. med. Anne Guertler, MD Department of Dermatology and Allergy University Hospital, LMU Munich

Frauenlobstrasse 9–11 80337 Munich, Germany

E-mail: a.guertler@med.uni-muenchen.de

References

1 Baldwin H, Tan J. Effects of diet on acne and its response to treatment. Am J Clin Dermatol 2020; 22: 55–65.

- 2 Melnik BC. Acne vulgaris: The metabolic syndrome of the pilosebaceous follicle. Am J Clin Dermatol 2018; 36(1): 29–40.
- Balić A, Vlašić D, Žužul K et al. Z. Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases. Int J Mol Sci 2020; 21(3): 741.
- 4 Thomsen BJ, Chow EY, Sapijaszko MJ. The potential uses of omega-3 fatty acids in dermatology: a review. J Cutan Med Surg 2020; Vol. 24(5): 481–94.
- 5 Rubin MG, Kim K, Logan AC. Acne vulgaris, mental health and omega-3 fatty acids: a report of cases. Lipids Health Dis 2008; 7: 36.
- 6 Khayef G, Young J, Burns-Whitmore B, Spalding T. Effects of fish oil supplementation on inflammatory acne. Lipids Health Dis 2012; 11: 165.
- 7 Jung JY, Kwon HH, Hong JS et al. Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial. Acta Derm Venereol 2014; 94(5): 521–5.
- 8 von Schacky C. Verwirrung um die Wirkung von Omega-3-Fettsäuren: Betrachtung von Studiendaten unter Berücksichtigung des Omega-3-Index. Internist (Berl) 2019; 60(12): 1319–27.
- 9 Flock MR, Skulas-Ray AC, Harris WS et al. Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. J Am Heart Assoc 2013; 2(6): e000513.